ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.
Clinicians discuss the rapidly evolving therapies, technology, and surgical approaches for early-stage NSCLC and take a fresh look at the future of care. Teamwork: A Multidisciplinary Approach to ...
Roche’s move into the digital pathology category has been boosted by FDA approval of a lab instrument and toolkit for use as an aid to clinical diagnosis. The clearance covers Roche’s Ventana DP 200 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results